The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XLIII.ag

Obstructive airway dysfunction (see also IVc, XVx)

Publications

Kissoonsingh P, Sutton B, Iqbal SU, Pallan L, Steven N, Khoja L

Eosinophilic Asthma Secondary to Adjuvant Anti-PD-1 Immune Checkpoint Inhibitor Treatment in a Melanoma Patient.

Case reports in oncological medicine 2022;2022;2658136 — 2022 — 2658136

Marcus K, Lee DJ, Wilson JS, Smith RJH, Puricelli M

Pembrolizumab Induced Acute Persistent Airway Disease in a Patient with Recurrent Respiratory Papillomatosis (RRP).

The Annals of otology, rhinology, and laryngology 2021 May 30;;34894211021276 — 2021 May 30 — 34894211021276

Blanchard A, Bouchard N

Pembrolizumab-induced obstructive bronchiolitis in a patient with stage IV non-small-cell lung cancer.

Current oncology (Toronto, Ont.) 2019 Aug;26;e571-e573 — 2019 Aug — e571-e573